Details for New Drug Application (NDA): 207621
✉ Email this page to a colleague
The generic ingredient in TROXYCA ER is naltrexone hydrochloride; oxycodone hydrochloride. There are nineteen drug master file entries for this compound. Additional details are available on the naltrexone hydrochloride; oxycodone hydrochloride profile page.
Summary for 207621
| Tradename: | TROXYCA ER |
| Applicant: | Pfizer |
| Ingredient: | naltrexone hydrochloride; oxycodone hydrochloride |
| Patents: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 207621
Generic Entry Date for 207621*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 1.2MG;10MG | ||||
| Approval Date: | Aug 19, 2016 | TE: | RLD: | No | |||||
| Patent: | 7,815,934 | Patent Expiration: | Dec 12, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 2.4MG;20MG | ||||
| Approval Date: | Aug 19, 2016 | TE: | RLD: | No | |||||
| Patent: | 7,815,934 | Patent Expiration: | Dec 12, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 3.6MG;30MG | ||||
| Approval Date: | Aug 19, 2016 | TE: | RLD: | No | |||||
| Patent: | 7,815,934 | Patent Expiration: | Dec 12, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Expired US Patents for NDA 207621
Complete Access Available with Subscription
